The short answer
Have black psyllium seed reviewed if you have troublesome stomach symptoms while using dulaglutide. A specific combined GI injury rate has not been established.
What this answer covers
Plantago afra seed, with Plantago indica included only where the monograph does so; not automatically Plantago ovata husk.
- Supplement or preparation
- Plantago afra
- Medication ingredient
- dulaglutide
Why symptoms change the advice
Dulaglutide can cause significant gastrointestinal symptoms and is not recommended with severe gastroparesis. Black psyllium seed requires care in people with swallowing problems, narrowing or possible obstruction. These are reasons for individualized review, not proof that the combination routinely injures the gut.
Use the right psyllium product
The monograph covers Plantago afra and Plantago indica seeds and requires sufficient liquid. Do not swallow a bulk-forming seed product dry or assume instructions for another psyllium species or husk are identical. Follow the specific product and clinician’s directions.
Slower emptying does not prove malabsorption
Dulaglutide delayed peaks for some tested oral medicines, but researchers judged their absorption changes not clinically relevant. That does not prove universal supplement safety, nor does it justify calling every nutrient poorly absorbed. The medicine itself is injected.
When to seek assessment
Do not self-treat abdominal pain with nausea, vomiting or failure to pass stool by adding more psyllium. Seek prompt medical advice; difficulty swallowing or breathing, severe persistent abdominal pain or inability to keep fluids down needs urgent assessment.
Keep the prescribed medicine plan
Continue the prescribed once-weekly injection plan. Tell the clinician about reduced eating, persistent vomiting or diarrhea and all other diabetes medicines. A supplement is not a reason to alter the injection dose yourself.
Evidence and practical considerations
Side effects & toxicity
Conditional concern relates to bulk-forming seed and pre-existing swallowing, obstruction or severe motility problems alongside dulaglutide GI effects. Exact-pair injury is unmeasured; delayed gastric emptying does not establish intestinal paralysis or universal oral nutrient malabsorption.
- Exact scope
- Plantago afra seed, with Plantago indica included only where the monograph does so; not automatically Plantago ovata husk. with Exact dulaglutide once-weekly subcutaneous solution injection. Exact RxNorm IN1551291; TRULICITY subcutaneous once-weekly product, not oral semaglutide or an oral nutrient. Dose-dependent gastric emptying and concomitant medicines matter.
- Medication form and route
- subcutaneous
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact Plantago afra-dulaglutide human study. The herbal monograph provides product precautions, not a tested weekly-injection spacing rule; oral-drug studies at 1.5 mg cannot establish all supplement or higher-dose outcomes.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed dulaglutide.
Glucose-dependent effects, delayed gastric emptying and gastrointestinal adverse reactions; increased hypoglycemia risk with insulin or insulin secretagogues. Tested oral-drug absorption not affected to clinically relevant degree at 1.5 mg.
How this applies: Exact RxNorm IN1551291; TRULICITY subcutaneous once-weekly product, not oral semaglutide or an oral nutrient. Dose-dependent gastric emptying and concomitant medicines matter.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: official herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of specified Plantago afra or Plantago indica seed preparations.
Contraindications include swallowing and gastrointestinal narrowing/obstruction concerns; adequate fluid matters. Motility-reducing medicines require medical supervision.
How this applies: Exact afra species included, but seed preparation and symptoms must be verified.
Not Plantago ovata husk or a direct dulaglutide study; no proven combined GI injury rate.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy subjects in four clinical pharmacology studies.
Peak concentrations generally lower and delayed; total exposures generally similar except atorvastatin reduction, judged not clinically relevant for the tested medicines.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Not Plantago, nutrient absorption or all higher dulaglutide doses; no dose adjustment recommendation applies only to tested drugs.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: dd9ee51c36a057b0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.